Pharmacological effects and clinical application of pemetinib/pemetinib

Pemigatinib/Pemigatinib is an FGFR (fibroblast growth factor receptor) inhibitor. As a targeted drug, it inhibits the growth and spread of cancer cells by blocking the FGFR signaling pathway. In clinical application, pemetinib is mainly used to treat patients with cholangiocarcinoma with FGFR gene mutations, especially those who have received other treatments but with poor results. In addition, it is exploring use to treat other FGFR-mutated malignancies. The emergence of pemetinib provides a new treatment option for these patients, but it may also be associated with some side effects. Therefore, when using it, the pros and cons need to be weighed according to the patient's condition to ensure the safety and effectiveness of the treatment.